Format

Send to

Choose Destination
Curr Atheroscler Rep. 2015 Dec;17(12):72. doi: 10.1007/s11883-015-0550-5.

Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention.

Author information

1
Department of Cardiology, University of Chicago Pritzker School of Medicine, Chicago, IL, USA. Bryan.Smith2@uchospitals.edu.
2
Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA. smich@mail.med.upenn.edu.
3
Department of Cardiology, University of Chicago Pritzker School of Medicine, Chicago, IL, USA. mdavidso@bsd.uchicago.edu.

Abstract

With the goal of decreasing low-density cholesterol (LDL-C) to mitigate risk of both primary and secondary cardiovascular outcomes, statins have been the cornerstone of therapy, significantly reducing the incidence of coronary atherosclerotic vascular disease. Previous studies suggest that adding other non-statin LDL-lowering agents may further lower LDL-C without negative side effects. Recent guidelines support the hypothesis that driving the LDL-C level below previously recommended targets may have a beneficial effect. Ezetimibe, a cholesterol absorption blocker that inhibits the Niemann-Pick C1-Like 1 (NPC1L1) receptor, has been the focus of recent trials that support its use in cardiovascular risk reduction. For patients not at goal on statin therapy alone, ezetimibe has proven to be a safe, well-tolerated medication that may be used as an adjunct to statin therapy to further reduce LDL-C, resulting in a significant mortality benefit.

KEYWORDS:

Cholesterol; Ezetimibe; LDL; LDL hypothesis; Vytorin

PMID:
26490081
DOI:
10.1007/s11883-015-0550-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center